DexCom reported Q3 2024 revenue of $994.2 million, up 2% YoY, with international revenue growing 12% while U.S. revenue declined 2%. GAAP operating income was $152 million or 15.3% of revenue, down 580 basis points YoY. The company maintained its full-year 2024 guidance targeting revenue of $4.00-4.05 billion.The quarter saw strategic advances including the launch of Stelo, DexCom's first over-the-counter glucose biosensor for adults with prediabetes and type 2 diabetes not on insulin therapy. The company also expanded internationally with Dexcom G7 launch in Australia and Dexcom ONE+ in France. Additionally, DexCom executed a $750 million share repurchase program.The company announced that Chief Commercial Officer Teri Lawver will retire at year-end, with CEO Kevin Sayer assuming interim leadership of commercial operations while conducting a global search for successor. DexCom ended Q3 with $2.49 billion in cash and marketable securities, maintaining strong financial flexibility for production expansion and market opportunities.

DexCom reported Q3 2024 revenue of $994.2 million, up 2% YoY, with international revenue growing 12% while U.S. revenue declined 2%. GAAP operating income was $152 million or 15.3% of revenue, down 580 basis points YoY. The company maintained its full-year 2024 guidance targeting revenue of $4.00-4.05 billion.The quarter saw strategic advances including the launch of Stelo, DexCom's first over-the-counter glucose biosensor for adults with prediabetes and type 2 diabetes not on insulin therapy. The company also expanded internationally with Dexcom G7 launch in Australia and Dexcom ONE+ in France. Additionally, DexCom executed a $750 million share repurchase program.The company announced that Chief Commercial Officer Teri Lawver will retire at year-end, with CEO Kevin Sayer assuming interim leadership of commercial operations while conducting a global search for successor. DexCom ended Q3 with $2.49 billion in cash and marketable securities, maintaining strong financial flexibility for production expansion and market opportunities.